Buy Sovaldi Online

Sovaldi is the brand name a 400mg pill of the drug Sofosbuvir , which is a direct acting antiviral medication used to treat chronic hepatitis C. It is manufactured and marketed by Gilead Sciences in the USA. To reduce prices in poorer countries GILEAD has granted licenses for its manufacturing and sales in India and Asia.

Sovaldi is a direct-acting antiviral (DAA) that works by inhibiting the replication of the hepatitis C virus in the body. It is often used in combination with other antiviral medications, such as Daclatasvir or Velpatasvir or Ledipasvir depending on individual factors such as the genotype of the virus and the patient’s medical history. For example the combination of Sofosbuvir + Ledipasvir is called Harvoni and is highly effective against Hepatitis C genotypes 1 and 4. The Combination of Sofosbuvir with Daclatasvir is highly effective against all genotypes of Hep C if the patient does not have liver cirrhosis.

The combination of sofosbuvir and daclatasvir is a highly effective treatment for Hepatitis C virus (HCV) infection. Here are some of the key benefits associated with this combination therapy:

1. High Cure Rates: Sofosbuvir and daclatasvir combination therapy has demonstrated high cure rates for various genotypes of HCV. Cure rates typically exceed 97%, even for patients with advanced liver disease or those who have not responded well to previous treatments.
2. Pan-Genotypic Efficacy: One of the significant advantages of this combination is its pan-genotypic efficacy. It has shown effectiveness against multiple genotypes of the Hepatitis C virus, making it a versatile treatment option that can be used across diverse patient populations.
3. Oral Administration: Both sofosbuvir and daclatasvir are oral medications, making them more convenient for patients compared to older interferon-based treatments, which often involved injections and had more side effects.
4. Shorter Treatment Duration: The treatment duration with sofosbuvir and daclatasvir is relatively short compared to previous HCV treatments. In many cases, the therapy can last as little as 8 to 12 weeks, depending on the patient’s genotype and other factors.
5. Improved Safety Profile: Compared to older HCV treatments, sofosbuvir and daclatasvir have a more favorable safety profile with fewer side effects. This makes the treatment more tolerable for patients and increases the likelihood of completing the prescribed course.
6. Reduced Risk of Liver Complications: Successful treatment with sofosbuvir and daclatasvir can lead to sustained virologic response (SVR), which means that the virus is undetectable in the blood six months after completing the treatment. Achieving SVR is associated with a reduced risk of liver cirrhosis, hepatocellular carcinoma (liver cancer), and other complications related to chronic HCV infection.
7. Combination Therapy: The combination of sofosbuvir and daclatasvir works by targeting different stages of the HCV life cycle, providing a more comprehensive and effective approach to viral eradication. This combination approach helps minimize the risk of developing drug-resistant strains of the virus.

It’s important to note that the specific treatment plan may vary based on individual patient characteristics, including genotype, liver health, and any previous treatment history.

In the USA Sovaldi can be quite expensive, especially without insurance coverage or assistance programs. However, different regions and countries may have different pricing structures to help make the medication more affordable for those in need. For example in India a 12 week treatment using Sovaldi will not cost more than US$400. To get the best Hep C treatment outcome Sovaldi (Sofosbuvir 400 mg) should be combined with Daclatasvir. A 12 weeks treatment with the combination of Sofosbuvir 400 mg + Daclatasvir 60 mg will cost US$550 total.

If you live in the USA and do not have health insurance, Gilead Sciences, the manufacturer of Sovaldi, may have patient assistance programs or discounts available for eligible individuals who meet strict criteria related to income and other factors.

Gilead has taken a lot of criticism for the extremely high price of Sovaldi (sofosbuvir) and has claimed several factors contribute to its expensive price:

1. Research and Development Costs: Gilead Sciences, the manufacturer of Sovaldi, claimed to have invested significant resources in the research and development of the drug. However in actual fact whistle blowers from within Gilead claimed that Gilead spends more on marketing than on research.
2. Limited Competition: Sovaldi was the first direct-acting antiviral (DAA) approved for the treatment of hepatitis C. Initially, it had no direct competitors in the market, which allowed Gilead Sciences to set a higher price for the drug.
3. High Cure Rates: Sovaldi has demonstrated high cure rates for hepatitis C, especially for genotype 1, which is the most prevalent genotype in many countries. The high efficacy and improved treatment outcomes contributed to the perception of Sovaldi as a breakthrough medication, which allowed the manufacturer to price it at a premium.
4. Value-based Pricing: Sovaldi’s pricing is often based on its perceived value and the potential cost savings it offers in the long term. Successful treatment with Sovaldi can prevent liver damage, cirrhosis, liver cancer, and the need for liver transplants, which may result in significant healthcare cost savings over time.
5. Patent Protection: Gilead Sciences holds patents for Sovaldi, providing them with exclusivity to market and sell the drug for a specific period. During this time, they have the ability to set prices without generic competition.

It’s worth noting that the high cost of Sovaldi has sparked debates and discussions regarding the affordability of life-saving medications, access to treatment, and the sustainability of healthcare systems. Governments, advocacy groups, and healthcare organizations have been working to address these issues and increase access to affordable hepatitis C treatments.